MP
VSEEW

Mangrove Partners’s VSee Health Warrant VSEEW Stock Holding History

Mangrove Partners’s Portfolio VSEEW Stock Details VSEEW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-500,000
Closed -$5.01M – 395
2022
Q2 		$5.01M Hold
500,000
– – 0.25% 102
2022
Q1 		$5M Buy
+500,000
New +$117K 0.27% 72

Other funds holding VSEEW

BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return
RCM
Radcliffe Capital Management Bala Cynwyd, Pennsylvania $1.33B AUM 1.18% 1-Year Est. Return
CAC
Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return
EFI
EHP Funds Inc Toronto, Canada $43.6M AUM 69.08% 1-Year Est. Return
ICM
Ionic Capital Management New York $1.37B AUM 48.26% 1-Year Est. Return
AI
Arena Investors Purchase, New York $12.5M AUM 0.27% 1-Year Est. Return
MI
MMCAP International Grand Cayman, Cayman Islands $1.16B AUM 77.9% 1-Year Est. Return
LA
Linden Advisors New York $17.9B AUM 1.72% 1-Year Est. Return
CS
Clear Street New York $24.6B AUM 56.26% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Mangrove Partners's VSEEW Position: Q3 2022 in Review

Mangrove Partners sold out of VSee Health Warrant (VSEEW) in Q3 2022, closing a stake of 500,000 shares — an estimated $5.01M sold.

Mangrove Partners first reported a position in VSEEW in Q1 2022 and held it in 2 quarters. The position peaked at $5.01M in Q2 2022. 30 funds tracked by Wall St. Rank hold VSEEW as of Q3 2022.

  • Mangrove Partners reported no remaining VSee Health Warrant position as of Q3 2022 after selling out during the quarter.
  • Mangrove Partners sold 500,000 VSee Health Warrant shares in Q3 2022, an estimated $5.01M.
  • Mangrove Partners first reported a position in VSee Health Warrant in Q1 2022 and held it in 2 quarters.
  • Mangrove Partners's VSee Health Warrant position peaked at $5.01M in Q2 2022.
  • 30 funds tracked by Wall St. Rank held VSee Health Warrant as of Q3 2022.

Based on Mangrove Partners's 13F filing for Q3 2022, filed 14 Nov 2022.